stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Return on equity
Travere Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was −252.8%, down 223.4 percentage points from fiscal 2025 (−29.4%). Over the past ten years it has ranged from −247.5% (fiscal 2024) to 89.3% (fiscal 2015); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of −52.0% and below the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −29.4% | 218.07 |
| FY2024 | −247.5% | (156.01) |
| FY2023 | −91.4% | 70.02 |
| FY2022 | −161.5% | (91.29) |
| FY2021 | −70.2% | 8.20 |
| FY2020 | −78.4% | (24.08) |
| FY2019 | −54.3% | (20.70) |
| FY2018 | −33.6% | (13.71) |
| FY2017 | −19.9% | (4.12) |
| FY2016 | −15.8% | (105.01) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 92.2% |
| MANE Veradermics Incorporated compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| CRSP CRISPR Therapeutics AG compare | −25.6% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| ERAS Erasca, Inc. compare | −78.3% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| TVTX Travere Therapeutics, Inc. | −252.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement